These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12723945)

  • 1. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
    Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Duan JJ; Lu Z; Xue CB; He X; Seng JL; Roderick JJ; Wasserman ZR; Liu RQ; Covington MB; Magolda RL; Newton RC; Trzaskos JM; Decicco CP
    Bioorg Med Chem Lett; 2003 Jun; 13(12):2035-40. PubMed ID: 12781190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
    Xue CB; Voss ME; Nelson DJ; Duan JJ; Cherney RJ; Jacobson IC; He X; Roderick J; Chen L; Corbett RL; Wang L; Meyer DT; Kennedy K; DeGradodagger WF; Hardman KD; Teleha CA; Jaffee BD; Liu RQ; Copeland RA; Covington MB; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Aug; 44(16):2636-60. PubMed ID: 11472217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
    Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse hydroxamate-based selective TACE inhibitors.
    Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
    Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
    Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
    Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
    Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
    J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.
    Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4293-7. PubMed ID: 14643312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
    Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
    Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.